Nicotine lozenges and behavioural interventions may help smokeless tobacco users to quit
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Commentary
Smokeless tobacco is used by more than 300 million people, 90% of whom live in Southeast Asia. 1 Whilst I would imagine most in the dental profession are familiar with the health consequences of smoking tobacco, some may be less familiar with those encountered by users of smokeless tobacco.
The evidence around smokeless tobacco and oral and general health is less substantial than it is for smoked tobacco and where there is evidence it seems to be contradictory. A recent systematic review and meta-analysis suggested that use of smokeless tobacco in Scandinavia had no effect on oral cancer rates, for example, and yet in the USA the relative risk was 2.6 (that is, smokeless tobacco users were 2.6 times more likely to get oral cancer than non-users). 2 In another review of longitudinal observational studies in Southeast Asia the odds ratio of getting oral cancer from chewing smokeless tobacco was 2.9 when only cohort studies were included, 3 which is not too dissimilar to the US relative risk (when the odds ratio is low it approximates the relative risk).
Relatively few studies appear to have looked at the impact of smokeless tobacco use on other health conditions, 4 though one prospective cohort study found that smokeless tobacco use in a Swedish population was associated with a relative risk of 1.4 (95% CI 1.2-1.6) for cardiovascular disease compared to non-users. 5 This systematic review is well conducted and helps us to understand the available interventions that have been tested using randomised controlled trials and pseudo-randomised controlled trials, and that followed up participants for over six months. Nine of the 34 studies included have been reported since the last update in 2011 and there is one trial that is ongoing. There seems to be a lot of activity in this field but, as we will see later, there appears to be a lack of research in the countries that have the most to gain from effective interventions.
Pharmacological interventions
The majority of these studies included a behavioural intervention in both the intervention and control arms. Thus the controls were not 'no treatment', but included in themselves what might well have been an effective intervention (see behavioural interventions below).
Bupropion, an antidepressant, has been shown to be effective in helping smokers to quit 6 but in this review the two studies found no effect on smokeless tobacco use quitting.
Nicotine lozenges did show an improvement in quit rates with a relative risk of 1.36 (95% CI 1.17-1.59). That is, those using lozenges compared to placebo were 36% more likely to give up. This paper is based on a Cochrane Review published in the Cochrane Library 2015, issue 10 (see www.thecochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and the Cochrane Library should be consulted for the most recent version of the review.
Nicotine gum and patches did not tend towards a significant benefit over placebo.
Varenecline, which has also been shown to be beneficial in helping smokers quit was similar in effect to the nicotine lozenges, with a relative risk of abstinence of 1.34 (95% CI 1.08-1.68).
Behavioural interventions
The seven studies that selected participants who were already motivated to stop using smokeless tobacco had an overall relative risk of abstinence from tobacco of 1.39 (95% CI 1.25-1.55). In those studies that selected anyone to participate the relative risk was only marginally lower at 1.37 (95% CI 1.23-1.53).
By including telephone support in the intervention the relative risk increased to 1.77 (95% CI 1.57-2.00). When an oral examination was combined with telephone support the relative risk increased to 2.07 (95% CI 1.61-2.66). That is, the likelihood of long-term abstinence is doubled.
These long-term quit rates may seem modest. If we were to assume that the unaided quit rate is two in 100 then by using behavioural techniques an additional one or two smokeless tobacco users in a 100 will give up. In the unrealistic event that these interventions were offered to the 300 million smokeless tobacco users in the world, instead of 1.5 million giving up alone an additional 750,000 to 1.5 million people would benefit.
There is a problem, though. Whilst no fault of the authors of this review, given that more than 90% of the population using 
